Zaki Hosny
Keine laufenden Positionen mehr
Profil
Zaki Hosny formerly worked at Motif BioSciences, Inc., as Chief Executive Officer & Deputy Chairman from 2011 to 2013, Motif Bio Plc, as Independent Non-Executive Director from 2006 to 2019, and Merck & Co., Inc., as Principal from 1998 to 2007.
Mr. Hosny received his graduate degree from the University of Cambridge.
Ehemalige bekannte Positionen von Zaki Hosny
| Unternehmen | Position | Ende |
|---|---|---|
| MOTIF BIO PLC | Direktor/Vorstandsmitglied | 15.11.2019 |
| MERCK & CO., INC. | Corporate Officer/Principal | 01.01.2007 |
Motif BioSciences, Inc.
 Motif BioSciences, Inc. Pharmaceuticals: MajorHealth Technology Motif BioSciences, Inc. develops antibiotics designed to be effective against serious and life-threatening infections. The company was founded on June 8, 2004 and is headquartered in New York, NY. | Präsident | 26.06.2013 |
Ausbildung von Zaki Hosny
| University of Cambridge | Graduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| MERCK & CO., INC. | Health Technology |
| Private Unternehmen | 2 |
|---|---|
Motif BioSciences, Inc.
Motif BioSciences, Inc. Pharmaceuticals: MajorHealth Technology Motif BioSciences, Inc. develops antibiotics designed to be effective against serious and life-threatening infections. The company was founded on June 8, 2004 and is headquartered in New York, NY. | Health Technology |
Motif Bio Plc
 Motif Bio Plc Pharmaceuticals: MajorHealth Technology Motif Bio Plc is a clinical stage biopharmaceutical company, which engages in the development and commercialization of pharmaceutical formulations. The company focuses on developing novel antibiotics designed to be effective against serious and life-threatening infections caused by multi-drug resistant bacteria. It offers Iclaprim, a novel diaminopyrimidine antibiotic that inhibits an essential bacterial enzyme called dihydrofolate reductase. The company was founded by Jonathan E. Gold on November 20, 2014 and is headquartered in Princeton, NJ. | Health Technology |
